CDK6 and breast carcinoma: As a proof-of-concept, focused follow-up studies silencing either RB1 or CDK6 led to significant alteration of drug sensitivity of MCF7 breast cancer cells to CDK4/6i (Fig. 1b, c), supporting the reliability of our in vitro screening results.